# GT Biopharma, Inc. (GTBP)

> Source: Nexqual · https://nexqual.com/GTBP · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, GT Biopharma, Inc. (GTBP), nexqual.com/GTBP" · informational, not investment advice.

**Price:** USD 7.36 (+18.52% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.21 · day 6.5–7.4 · 52w 4.91–28.75 · market cap $15.2M · NCM

## Key facts
- Total return with dividends: 1Y +979.2% vs S&P 500 +18.1%; 5Y -95.9% vs S&P 500 +85.1%.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +979.2% | -95.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +988.0% | -47.2% |
| Volatility (annualized) | 982.9% | 276.7% |
| Max drawdown | -97.0% (Aug 2026→Sep 2026) | -99.9% (Nov 2021→Aug 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/GTBP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt